Critique Pembrolizumab (Keytruda): CADTH Reimbursement Advice: Indicator: Together with chemotherapy, for your treatment of adult individuals with locally recurrent unresectable or metastatic triple-negative breast cancer who've not acquired prior chemotherapy for metastatic ailment and whose tumours Convey programmed mobile Demise-ligand 1 (blended beneficial rating ≥ 10) as determin... https://juliusbdeon.thezenweb.com/a-review-of-keytruda-cost-73917582